A treatment developed by Chelsea Therapeutics International Ltd for a rare type of low blood pressure is presenting problems for U.S. drug reviewers at the U.S. Food and Drug Administration. A review, posted on the FDA’s website on Friday, comes ahead of a meeting on Jan. 14 of outside medical experts who will discuss the drug and recommend whether it should be approved. The FDA generally follows the advice of its advisory panels. The drug, droxidopa, is designed to treat neurogenic orthostatic hypotension (NOH), a rare, chronic type of low blood pressure that occurs on standing.
Help employers find you! Check out all the jobs and post your resume.
